menu015.png

Investor search in Quimatryx

Quimatryx has hired NORGESTION to search for one or more partners to rise €3 Million in two planned financial rounds between 2018 and 2019. This amount will be used to develop Quimatryx compound QTX125 (selective inhibitor against HDAC6) to clinical phase I for mantle cell lymphoma.

 

   QUIMATRYX

   Paseo Mikeletegi 69, 3ª planta

   20009 San Sebastián

   Tel: 946 08 70 37

   www.quimatryx.com